Literature DB >> 3764805

Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect.

F Fernandez, P N'guyen, J Van Ryn, F A Ofosu, J Hirsh, M R Buchanan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3764805     DOI： 10.1016/0049-3848(86)90094-0

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  13 in total

1.  Management of hemorrhagic events in patients receiving anticoagulant therapy.

Authors:  D G Love
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.

Authors:  U Klinkhardt; J Graff; D Westrup; C M Kirchmaier; H U Esslinger; H K Breddin; S Harder
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

4.  Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.

Authors:  Richard C Becker; Kenneth W Mahaffey; Hongqiu Yang; A J Marian; Mark I Furman; A Michael Lincoff; Stanley L Hazen; John L Petersen; Craig J Reist; Neal S Kleiman
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

Review 5.  The pathogenesis and prevention of thromboembolic complications in patients undergoing total hip replacement.

Authors:  D K Potyk; H J Tabbarah
Journal:  J Gen Intern Med       Date:  1993-04       Impact factor: 5.128

6.  Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.

Authors:  J F Eidt; P Allison; S Noble; J Ashton; P Golino; J McNatt; L M Buja; J T Willerson
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

Review 7.  Anticoagulation therapy in children.

Authors:  Milind D Ronghe; Christina Halsey; Nicholas J Goulden
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans.

Authors:  Jochen Graff; Ute Klinkhardt; Dagmar Westrup; Carl M Kirchmaier; Hans Klaus Breddin; Sebastian Harder
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 9.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 10.  Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.

Authors:  Jawed Fareed; Debra Hoppensteadt; Jeanine Walenga; Omer Iqbal; Qing Ma; Walter Jeske; Taqdees Sheikh
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.